Pines Wealth Management LLC Has $278,000 Stake in Pfizer Inc. (NYSE:PFE)

Pines Wealth Management LLC trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 4.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,962 shares of the biopharmaceutical company’s stock after selling 480 shares during the quarter. Pines Wealth Management LLC’s holdings in Pfizer were worth $278,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Mcdonald Partners LLC increased its position in Pfizer by 9.9% during the fourth quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company’s stock worth $2,926,000 after buying an additional 9,963 shares during the last quarter. Bank of Jackson Hole Trust acquired a new position in Pfizer during the fourth quarter worth $264,000. Harvey Capital Management Inc. acquired a new stake in shares of Pfizer in the fourth quarter valued at about $544,000. ING Groep NV grew its position in shares of Pfizer by 48.6% in the fourth quarter. ING Groep NV now owns 1,013,230 shares of the biopharmaceutical company’s stock valued at $26,881,000 after purchasing an additional 331,403 shares during the last quarter. Finally, WCM Investment Management LLC grew its position in shares of Pfizer by 128.7% in the fourth quarter. WCM Investment Management LLC now owns 115,913 shares of the biopharmaceutical company’s stock valued at $3,062,000 after purchasing an additional 65,238 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $25.00 price target (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Finally, UBS Group raised their price target on Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have assigned a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Moderate Buy” and a consensus target price of $29.17.

Pfizer Stock Up 1.0%

NYSE PFE opened at $23.36 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The firm has a 50-day simple moving average of $22.95 and a 200 day simple moving average of $25.00. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The stock has a market cap of $132.81 billion, a PE ratio of 16.57, a PEG ratio of 0.64 and a beta of 0.57.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to analysts’ expectations of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm’s revenue was down 7.8% on a year-over-year basis. During the same quarter last year, the company earned $0.82 earnings per share. On average, research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.36%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer’s dividend payout ratio is 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.